Evaluating a new imaging method for clear cell renal cell carcinoma
Evaluation of Diagnostic Value of 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
This study is testing a new imaging method using a special probe to see if it can better help doctors diagnose clear cell renal cell carcinoma in Chinese patients compared to the standard imaging method.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06519760 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the diagnostic value of a specific probe, 68Ga-C1, in PET/CT imaging for patients with clear cell renal cell carcinoma. The study will compare the effectiveness of 68Ga-C1 PET/CT imaging against the standard 18F-FDG PET/CT imaging in diagnosing renal masses. Additionally, it will evaluate the safety, tolerability, and radiation dosimetry associated with the use of 68Ga-C1. The trial focuses on Chinese patients with either confirmed or suspected clear cell renal cell carcinoma.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with confirmed or suspected clear cell renal cell carcinoma.
Not a fit: Patients with renal masses known to be metastases from other primary tumors or those with other malignancies requiring treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more accurate imaging method for diagnosing clear cell renal cell carcinoma, potentially leading to better treatment outcomes.
How similar studies have performed: While this approach is novel in the context of clear cell renal cell carcinoma, similar imaging techniques have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signed written informed consent； 2. Age ≥18； 3. Patients with confirmed or suspected clear cell renal cell carcinoma; 4. Expected survival ≥6 months. Exclusion Criteria: 1. Renal mass is known to be a metastasis of another primary tumor; 2. Have other malignancies that require treatment; 3. Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks; 4. Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL/min/1.73 m²; 5. Pregnant and lactating women or female patients plan to become pregnant within 6 months; 6. Uncontrolled psychiatric disorders; 7. Vulnerable population (e.g., being in detention) or have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease).
Where this trial is running
Beijing, Beijing Municipality
- Peking University First Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Kan Gong — Peking University First Hospital
- Study coordinator: Kan Gong
- Email: kan.gong@bjmu.edu.cn
- Phone: (86)-010-83572075
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.